One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab
NACompletedINTERVENTIONAL
Enrollment
37
Participants
Timeline
Start Date
April 1, 2016
Primary Completion Date
April 1, 2017
Study Completion Date
April 1, 2018
Conditions
Diabetic Macular Edema
Interventions
DRUG
Aflibercept Injection [Eylea]
intravitreal injection of Aflibercept in resistant DME.
All Listed Sponsors
lead
University of Alexandria
OTHER
NCT03974425 - One Year Results of Switching to Aflibercept for Persistent Diabetic Macular Edema Resistant to Bevacizumab | Biotech Hunter | Biotech Hunter